Methimazole (MMI) has been used in subjects with Graves' disease. Although in clinical
medicine its starting dose was dependent on the judgment of each physician in charge,
the Japan Thyroid Association treatment guidelines recommended that we should start
MMI at a dose of 15 mg/day especially in subjects with mild Graves' disease with a baseline free T4 (FT4) levels between 0.24 pmol/L (1.9 ng/dL) and 0.64 pmol/L (5 ng/dL) from the viewpoint of preventing side effects [
1
,
2
]. Based on such background, in this study we examined which background factors influence
on the effect of 15 mg/day of methimazole in Japanese subjects with mild Graves' disease.Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Medical guidelines for patients with Basedow disease.in: Initial doses of antithyroid drugs. Nankoudou, Tokyo. 2006: 47-55 ([In Japanease])
- Reference of diagnosis of Basedow disease. Nankoudou, Tokyo.2006: 7-10 ([In Japanease])
- Determinants of thyroid volume as measured by ultrasonography in healthy adults randomly selected.Clin Endocrinol (Oxf). 2000; 53: 629-634
- Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.Horm Metab Res. 2003; 35: 492-497
Article info
Publication history
Published online: September 03, 2016
Accepted:
August 24,
2016
Received in revised form:
August 20,
2016
Received:
August 17,
2016
Identification
Copyright
© 2016 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
